{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:12:09Z","timestamp":1791569529916,"version":"4.3.4"},"reference-count":254,"publisher":"Elsevier","isbn-type":[{"value":"9780323915113","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.armc.2021.09.004","type":"book-chapter","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T08:50:05Z","timestamp":1637139005000},"page":"49-107","source":"Crossref","is-referenced-by-count":4,"title":["Anno 2021: Which antivirals for the coming decade?"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.armc.2021.09.004_bb0010","series-title":"VBI-2901: Pan-Coronavirus Vaccine Candidate Overview, VBI Vaccines","first-page":"6","author":"VBI Vaccines","year":"2020"},{"key":"10.1016\/bs.armc.2021.09.004_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A New Coronavirus Associated With Human Respiratory Disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0020","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.1002\/anie.202008835","article-title":"Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2","volume":"60","author":"Su","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/bs.armc.2021.09.004_bb0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acsinfecdis.0c00874","article-title":"Early Returns on Small Molecule Therapeutics for SARS-CoV-2","volume":"7","author":"Namchuk","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0030","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1021\/acsinfecdis.0c00646","article-title":"Recent Insights Into Emerging Coronavirus: SARS-CoV-2","volume":"7","author":"Shang","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0035","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/bs.armc.2021.09.004_bb0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 Polymerase Stalling by Remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb0045","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0055","article-title":"Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the Parent Nucleoside GS-441524 Over Remdesivir for Covid-19 Treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0065","article-title":"Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs","author":"Schooley","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/bs.armc.2021.09.004_bb0070","article-title":"Repurposing Nucleoside Analogs for Human Coronaviruses","volume":"65","author":"Zandi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0075","doi-asserted-by":"crossref","first-page":"e02420","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105122","article-title":"A Robust SARS-CoV-2 Replication Model in Primary Human Epithelial Cells at the Air Liquid Interface to Assess Antiviral Agents","volume":"192","author":"Do","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0085","article-title":"Molnupiravir, an Oral Antiviral Treatment for COVID-19","author":"Fischer","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/bs.armc.2021.09.004_bb0090","first-page":"12","article-title":"An orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically Administered Ribonucleoside Analogue MK-4482\/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0105","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/j.jbc.2021.100867","article-title":"Decoding Molnupiravir-Induced Mutagenesis in SARS-CoV-2","volume":"297","author":"Men\u00e9ndez-Arias","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0110","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and Safety of Favipiravir in Treatment of COVID-19: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.armc.2021.09.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-Dependent RNA Polymerase in the Presence of Favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.armc.2021.09.004_bb0120","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-Dependent RNA Polymerase (RdRp) Inhibitors: The Current Landscape and Repurposing for the COVID-19 Pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsmedchemlett.0c00485","article-title":"Influence of 4\u2032-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2","volume":"12","author":"Zheng","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/D1MD00066G","article-title":"A Review of the Latest Research on Mpro Targeting SARS-COV Inhibitors","volume":"12","author":"Yang","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0135","article-title":"Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19","author":"Boras","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/bs.armc.2021.09.004_bb0140","article-title":"An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19","author":"Owen","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/bs.armc.2021.09.004_bb0145","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro Inhibitors With Antiviral Activity in a Transgenic Mouse Model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/bs.armc.2021.09.004_bb0150","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acsmedchemlett.1c00140","article-title":"Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate","volume":"12","author":"Bobileva","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0155","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acsinfecdis.1c00131","article-title":"The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors","volume":"7","author":"Otava","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/bs.armc.2021.09.004_bb0165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza Virus: Dealing with a Drifting and Shifting Pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0170","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s12276-021-00603-0","article-title":"The Evolution and Future of Influenza Pandemic Preparedness","volume":"53","author":"Harrington","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0175","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/molecules26040880","article-title":"Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase Toward Inhibitor Design","volume":"26","author":"Mtambo","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/bs.armc.2021.09.004_bb0180","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1002\/jmv.26670","article-title":"Distribution and Evolution of H1N1 Influenza A Viruses With Adamantanes-Resistant Mutations Worldwide From 1918 to 2019","volume":"93","author":"He","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0185","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/bs.armc.2021.09.004_bb0190","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1021\/acsmedchemlett.8b00336","article-title":"Structure\u2013Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers","volume":"9","author":"Hu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/acs.jmedchem.7b01536","article-title":"In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors With Potent Antiviral Activity Against Drug-Resistant Influenza A Viruses","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0200","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.8b01065","article-title":"Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency Against Oseltamivir-Resistant N1-H274Y Variant","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0205","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1021\/acs.jmedchem.8b00929","article-title":"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0210","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/acsinfecdis.7b00265","article-title":"Inhibitors of Influenza A Virus Polymerase","volume":"4","author":"Yuan","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza Virus RNA Polymerase: Insights Into the Mechanisms of Viral RNA Synthesis","volume":"14","author":"te Velthuis","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0220","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0230","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1060028019826565","article-title":"Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza","volume":"53","author":"Yang","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0235","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/irv.12821","article-title":"Comprehensive Assessment of Amino Acid Substitutions in the Trimeric RNA Polymerase Complex of Influenza A Virus Detected in Clinical Trials of Baloxavir Marboxil","volume":"15","author":"Hashimoto","year":"2021","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/bs.armc.2021.09.004_bb0240","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1021\/acs.jmedchem.0c00565","article-title":"Non-Rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses","volume":"63","author":"Ivashchenko","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0245","doi-asserted-by":"crossref","first-page":"9438","DOI":"10.1021\/acs.jmedchem.9b00747","article-title":"SAR Exploration of Tight-Binding Inhibitors of Influenza Virus PA Endonuclease","volume":"62","author":"Credille","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0250","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1021\/acs.jmedchem.9b00861","article-title":"Synthesis and SAR Study of Carbamoyl Pyridone Bicycle Derivatives as Potent Inhibitors of Influenza Cap-dependent Endonuclease","volume":"62","author":"Miyagawa","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0255","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0260","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0265","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1021\/acs.jmedchem.9b01091","article-title":"Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region","volume":"62","author":"McGowan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10020273","article-title":"Favipiravir in Therapy of Viral Infections","volume":"10","author":"\u0141agocka","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0275","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00552","article-title":"Inhibition of Influenza Virus Polymerase by Interfering With Its Protein\u2013Protein Interactions","volume":"7","author":"Massari","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2015.11.005","article-title":"Identification of a Small-Molecule Inhibitor of Influenza Virus via Disrupting the Subunits Interaction of the Viral Polymerase","volume":"125","author":"Yuan","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0285","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of Influenza A Nucleoprotein as an Antiviral Target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/acs.jmedchem.9b01244","article-title":"Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein","volume":"63","author":"Woodring","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0295","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.jmedchem.8b01683","article-title":"Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents","volume":"62","author":"Sethy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0300","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/acsinfecdis.7b00120","article-title":"Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein","volume":"4","author":"White","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0305","doi-asserted-by":"crossref","first-page":"10951","DOI":"10.1021\/acs.jmedchem.1c00304","article-title":"Aryl Sulfonamide Inhibits Entry and Replication of Diverse Influenza Viruses via the Hemagglutinin Protein","volume":"64","author":"White","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0310","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1021\/acs.jmedchem.0c00312","article-title":"Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion","volume":"63","author":"Wu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0315","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/acs.jmedchem.9b01900","article-title":"Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic With Oseltamivir","volume":"63","author":"Gaisina","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0320","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a New Class of Anti-Influenza Molecules Targeting Viral Hemagglutinin at the Post-Translational Level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0325","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza: A Double-Blind, Randomised, Placebo-Controlled, Phase 2b\/3 Trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0330","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0335","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0340","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/acsinfecdis.9b00230","article-title":"An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes With Oseltamivir","volume":"5","author":"O'Hanlon","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0345","first-page":"3","article-title":"Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0350","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0355","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-Analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.armc.2021.09.004_bb0360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40121-020-00383-6","article-title":"The Future of Respiratory Syncytial Virus Disease Prevention and Treatment","volume":"10","author":"Domachowske","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/bs.armc.2021.09.004_bb0365","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","article-title":"State of the Art in Respiratory Syncytial Virus Drug Discovery and Development","volume":"62","author":"Cockerill","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0370","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.0c00226","article-title":"Discovery of 3-({5-Chloro-1- 3-(methylsulfonyl)propyl -1H-indol-2-yl}methyl)-1-(2,2,2 -trifluoroethyl)-1,3-dihydro-2H-imidazo 4,5-c pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus","volume":"63","author":"Vendeville","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0375","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.0c01882","article-title":"Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion","volume":"64","author":"Cockerill","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0380","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0385","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study","volume":"58","author":"Mackman","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0390","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/cid\/ciz1166","article-title":"A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0395","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/cid\/ciz1167","volume":"71","author":"Marty","year":"2020","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0400","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02312-19","article-title":"Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected With Respiratory Syncytial Virus","volume":"64","author":"Porter","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0405","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acsinfecdis.9b00524","article-title":"Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus","volume":"6","author":"Pribut","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0410","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/acsmedchemlett.0c00008","article-title":"Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins","volume":"11","author":"Yamaguchi-Sasaki","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009428","article-title":"EDP-938, a Novel Nucleoprotein Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities In Vitro and in a Non-Human Primate Model","volume":"17","author":"Rhodin","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.armc.2021.09.004_bb0420","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the Treatment of Respiratory RNA Virus Infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0425","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-019-14246-3","article-title":"Cryo-EM Structure of the Respiratory Syncytial Virus RNA Polymerase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb0430","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cell.2019.08.014","article-title":"Structure of the Respiratory Syncytial Virus Polymerase Complex","volume":"179","author":"Gilman","year":"2019","journal-title":"Cell"},{"key":"10.1016\/bs.armc.2021.09.004_bb0435","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0440","series-title":"\u03b2-D-2\u2032-Deoxy-2\u2032-Substituted-4\u2032-Substituted-2-Substituted-N6-Substituted-6-Aminopurine Nucleotides for the Treatment of Paramyxovirus and Orthomyxovirus Infections","author":"Sommadossi","year":"2018"},{"key":"10.1016\/bs.armc.2021.09.004_bb0445","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus With Efficacy in the African Green Monkey Model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0450","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human Rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/bs.armc.2021.09.004_bb0455","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/CMR.16.2.230-241.2003","article-title":"Importance of Respiratory Viruses in Acute Otitis Media","volume":"16","author":"Heikkinen","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/bs.armc.2021.09.004_bb0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/cea.12428","article-title":"How rhinovirus Infections Cause Exacerbations of Asthma","volume":"45","author":"Gern","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/bs.armc.2021.09.004_bb0465","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/JEP.S255211","article-title":"Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections","volume":"13","author":"Coultas","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2017.03.009","article-title":"Direct-Acting Antivirals and Host-Targeting Strategies to Combat Enterovirus Infections","volume":"24","author":"Bauer","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0475","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1021\/acsmedchemlett.8b00134","article-title":"3-Aryl-1,2,4-Oxadiazole Derivatives Active Against Human Rhinovirus","volume":"9","author":"Kim","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0480","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1021\/acs.jmedchem.8b00931","article-title":"Structure-Based Drug Design of Potent Pyrazole Derivatives Against Rhinovirus Replication","volume":"61","author":"Da Costa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0485","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/JVI.78.7.3663-3674.2004","article-title":"VP1 Sequencing of All Human Rhinovirus Serotypes: Insights Into Genus Phylogeny and Susceptibility to Antiviral Capsid-Binding Compounds","volume":"78","author":"Ledford","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0490","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12985-015-0330-4","article-title":"In Vitro Characterisation of a Pleconaril\/Pirodavir-Like Compound With Potent Activity Against Rhinoviruses","volume":"12","author":"Lacroix","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/bs.armc.2021.09.004_bb0495","doi-asserted-by":"crossref","first-page":"112007","DOI":"10.1016\/j.ejmech.2019.112007","article-title":"Novel pleconaril Derivatives: Influence of Substituents in the Isoxazole and Phenyl Rings on the Antiviral Activity Against Enteroviruses","volume":"188","author":"Egorova","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0500","doi-asserted-by":"crossref","first-page":"19109","DOI":"10.1073\/pnas.1904732116","article-title":"Cryo-EM Structure of Pleconaril-Resistant Rhinovirus-B5 Complexed to the Antiviral OBR-5-340 Reveals Unexpected Binding Site","volume":"116","author":"Wald","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.armc.2021.09.004_bb0505","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cmdc.201500304","article-title":"Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses","volume":"10","author":"Makarov","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.armc.2021.09.004_bb0510","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.01746-13","article-title":"Multiple Classes of Antiviral Agents Exhibit In Vitro Activity Against Human Rhinovirus Type C","volume":"58","author":"Mello","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0515","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1128\/JCM.40.11.4218-4223.2002","article-title":"Human Rhinovirus 87 and Enterovirus 68 Represent a Unique Serotype With Rhinovirus and Enterovirus Features","volume":"40","author":"Blomqvist","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0520","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1016\/S1473-3099(15)00543-5","article-title":"Global Emergence of Enterovirus D68: A Systematic Review","volume":"16","author":"Holm-Hansen","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0525","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/acsinfecdis.0c00120","article-title":"Enterovirus D68 Antivirals: Past, Present, and Future","volume":"6","author":"Hu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000904","article-title":"Rational Design of Highly Potent Broad-Spectrum Enterovirus Inhibitors Targeting the Nonstructural Protein 2C","volume":"18","author":"Bauer","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0535","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1021\/acs.jmedchem.9b00115","article-title":"Discovery of Quinoline Analogues as Potent Antivirals Against Enterovirus D68 (EV-D68)","volume":"62","author":"Musharrafieh","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0540","doi-asserted-by":"crossref","first-page":"8755","DOI":"10.1021\/acs.jmedchem.1c00758","article-title":"Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals Against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein","volume":"64","author":"Hu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0545","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola Virus Disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/bs.armc.2021.09.004_bb0550","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0166-3542(02)00200-0","article-title":"Defense Against Filoviruses Used as Biological Weapons","volume":"57","author":"Bray","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0555","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/cen-09923-feature1","article-title":"Vaccines Could Make Big Ebola Outbreaks a Thing of the Past","volume":"99","author":"Satyanarayana","year":"2021","journal-title":"C&EN Global Enterprise"},{"key":"10.1016\/bs.armc.2021.09.004_bb0560","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41591-021-01313-w","article-title":"The Need for a New Strategy for Ebola Vaccination","volume":"27","author":"Bausch","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0565","first-page":"13","article-title":"First Ebola Treatment Approved by FDA","volume":"98","author":"Satyanarayana","year":"2020","journal-title":"C&EN Global Enterprise"},{"key":"10.1016\/bs.armc.2021.09.004_bb0575","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2021.1881061","article-title":"Targeting Ebola Virus Replication Through Pharmaceutical Intervention","volume":"30","author":"Hansen","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/bs.armc.2021.09.004_bb0580","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic Strategies to Target the Ebola Virus Life Cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0585","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coviro.2019.03.001","article-title":"Current Status of Small Molecule Drug Development for Ebola Virus and Other Filoviruses","volume":"35","author":"Edwards","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0590","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1021\/acsmedchemlett.0c00025","article-title":"Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors","volume":"11","author":"Plewe","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb0595","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1021\/acs.jmedchem.0c00463","article-title":"Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections","volume":"63","author":"Gaisina","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0600","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small Molecule Inhibitors Reveal Niemann-Pick C1 is Essential for Ebola Virus Infection","volume":"477","author":"Cote","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0605","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1021\/acs.jmedchem.8b00704","article-title":"Identification of Potent Ebola Virus Entry Inhibitors With Suitable Properties for in Vivo Studies","volume":"61","author":"Liu","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0610","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/acsinfecdis.5b00130","article-title":"Cysteine Cathepsin Inhibitors as Anti-Ebola Agents","volume":"2","author":"van der Linden","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0615","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic Efficacy of the Small Molecule GS-5734 Against Ebola Virus in Rhesus Monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0620","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0625","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0630","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection Against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0635","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2014A Broad-Spectrum Antiviral Adenosine Nucleoside Analog Under Development for the Treatment of Ebola Virus Disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/bs.armc.2021.09.004_bb0640","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2015.10.010","article-title":"The Lipid Moiety of Brincidofovir is Required for In Vitro Antiviral Activity Against Ebola Virus","volume":"125","author":"McMullan","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0650","doi-asserted-by":"crossref","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental Treatment of Ebola Virus Disease With Brincidofovir","volume":"11","author":"Dunning","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.armc.2021.09.004_bb0655","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(00)00066-8","article-title":"Treatment of lethal Ebola Virus Infection in Mice with a Single Dose of an S-Adenosyl-L-Homocysteine Hydrolase Inhibitor","volume":"45","author":"Bray","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0660","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1086\/514316","article-title":"Antiviral Drug Therapy of Filovirus Infections: S-Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus In Vitro and in a Lethal Mouse Model","volume":"179","author":"Huggins","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0665","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.antiviral.2018.06.003","article-title":"Identification of a Small Molecule Inhibitor of Ebola Virus Genome Replication and Transcription Using In Silico Screening","volume":"156","author":"Easton","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0675","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV Preexposure Prophylaxis: A Review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/bs.armc.2021.09.004_bb0680","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and Tenofovir Alafenamide vs Emtricitabine and Tenofovir Disoproxil Fumarate for HIV pre-exposure Prophylaxis (DISCOVER): Primary Results From a Randomised, Double-blind, Multicentre, Active-controlled, Phase 3, Non-Inferiority Trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.armc.2021.09.004_bb0685","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug Resistance During HIV Pre-Exposure Prophylaxis","volume":"79","author":"Gibas","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/bs.armc.2021.09.004_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01514","article-title":"Modeling HIV Pre-Exposure Prophylaxis","volume":"10","author":"Straubinger","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0700","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.biochem.1c00157","article-title":"Long-Acting Cabotegravir for HIV\/AIDS Prophylaxis","volume":"60","author":"Engelman","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/bs.armc.2021.09.004_bb0705","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083","author":"Marzinke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0715","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/d41586-021-00618-7","article-title":"Achilles Heel Spotted for Promising HIV-Prevention Drug","volume":"591","author":"Maxmen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb0720","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COH.0000000000000599","article-title":"Islatravir for the Treatment and Prevention of Infection With the Human Immunodeficiency Virus Type 1","volume":"15","author":"Markowitz","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/bs.armc.2021.09.004_bb0725","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, Uptake, and Use of a Dapivirine Vaginal Ring for HIV-1 Prevention in African Women (HOPE): An Open-Label, Extension Study","volume":"8","author":"Baeten","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/bs.armc.2021.09.004_bb0730","series-title":"GS-6207 Sustained Delivery Formulation Supports 6-Month Dosing Interval","author":"Begley","year":"2020"},{"key":"10.1016\/bs.armc.2021.09.004_bb0735","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","article-title":"Mechanistic Insight into Antiretroviral Potency of 2\u2032-Deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine (FNC) With a Long-Lasting Effect on HIV-1 Prevention","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0740","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The Continued Threat of Emerging Flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0750","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow Fever Control: Current Epidemiology and Vaccination Strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel Med. Vac."},{"key":"10.1016\/bs.armc.2021.09.004_bb0760","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2214-109X(18)30024-X","article-title":"Existing and Potential Infection Risk Zones of Yellow Fever Worldwide: A Modelling Analysis","volume":"6","author":"Shearer","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/bs.armc.2021.09.004_bb0765","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64670","article-title":"The Global Burden of Yellow Fever","volume":"10","author":"Gaythorpe","year":"2021","journal-title":"Elife"},{"key":"10.1016\/bs.armc.2021.09.004_bb0770","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow Fever\u2014Once Again on the Radar Screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0775","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1038\/s41467-020-19625-9","article-title":"Risk of Yellow Fever Virus Transmission in the Asia-Pacific Region","volume":"11","author":"Lataillade","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb0780","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41467-020-16010-4","article-title":"Accelerating Invasion Potential of Disease Vector Aedes aegypti Under Climate Change","volume":"11","author":"Iwamura","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb0785","doi-asserted-by":"crossref","DOI":"10.1289\/EHP5899","article-title":"Current and Projected Distributions of Aedes aegypti and Ae. albopictus in Canada and the U.S","volume":"128","author":"Khan","year":"2020","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/bs.armc.2021.09.004_bb0790","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse Event Reports Following Yellow Fever Vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/bs.armc.2021.09.004_bb0795","article-title":"Nucleoside Analogs With Antiviral Activity Against Yellow Fever Virus","volume":"63","author":"Zandi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/bs.armc.2021.09.004_bb0800","article-title":"Yellow Fever Virus is Susceptible to Sofosbuvir Both In Vitro and In Vivo","author":"de Freitas","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0805","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.aohep.2019.09.001","article-title":"Sofosbuvir Inhibits Yellow Fever Virus In Vitro and in Patients With Acute Liver Failure","volume":"18","author":"Mendes","year":"2019","journal-title":"Ann. Hepatol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0810","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster Model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0815","doi-asserted-by":"crossref","first-page":"104899","DOI":"10.1016\/j.antiviral.2020.104899","article-title":"Remdesivir Triphosphate can Efficiently Inhibit the RNA-Dependent RNA Polymerase From Various Flaviviruses","volume":"182","author":"Konkolova","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0820","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejmech.2017.09.060","article-title":"Inhibitors of Yellow Fever Virus Replication Based on 1,3,5-Triphenyl-4,5-Dihydropyrazole Scaffold: Design, Synthesis and Antiviral Evaluation","volume":"141","author":"Fioravanti","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0825","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2019.03.004","article-title":"Broad Spectrum Anti-flavivirus Pyridobenzothiazolones Leading to Less Infective Virions","volume":"167","author":"Cannalire","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0830","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/v12030351","article-title":"Antiviral Activity of Benzavir-2 Against Emerging Flaviviruses","volume":"12","author":"Gwon","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/bs.armc.2021.09.004_bb0845","doi-asserted-by":"crossref","first-page":"e1172","DOI":"10.1016\/S2214-109X(21)00205-9","article-title":"Polio Eradication at the Crossroads","volume":"9","author":"Chumakov","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/bs.armc.2021.09.004_bb0850","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/bs.armc.2021.09.004_bb0860","doi-asserted-by":"crossref","first-page":"913","DOI":"10.15585\/mmwr.mm6928a4","article-title":"Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses\u2014Worldwide, July 2018-December 2019","volume":"69","author":"Macklin","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/bs.armc.2021.09.004_bb0865","first-page":"333","article-title":"Completing Polio Eradication: The Case for Antiviral Drugs","volume":"215","author":"Sutter","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0870","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00671-09","article-title":"In Vitro Antiviral Activity of V-073 Against Polioviruses","volume":"53","author":"Oberste","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0875","first-page":"335","article-title":"Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model","volume":"215","author":"Collett","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0880","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2013.03.003","article-title":"Anti-Poliovirus Activity of Protease Inhibitor AG-7404, and Assessment of In Vitro Activity in Combination With Antiviral Capsid Inhibitor Compounds","volume":"98","author":"Rhoden","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb0885","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/acs.jmedchem.7b01863","article-title":"Synthesis and Structure-Activity Relationship (SAR) Studies of Novel Pyrazolopyridine Derivatives as Inhibitors of Enterovirus Replication","volume":"61","author":"Xing","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0890","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/acsinfecdis.6b00116","article-title":"Cell-Based High-Throughput Screening Assay Identifies 2\u2032,2\u2032-Difluoro-2\u2032-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent","volume":"3","author":"Zhang","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0895","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/acs.jmedchem.8b01482","article-title":"In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors","volume":"62","author":"Madia","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0900","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C Virus Infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/bs.armc.2021.09.004_bb0905","first-page":"1","article-title":"An Update on Direct Antiviral Agents for the Treatment of Hepatitis C","author":"Stanciu","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/bs.armc.2021.09.004_bb0910","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.armc.2021.09.004_bb0915","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Review in Chronic Hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/bs.armc.2021.09.004_bb0920","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jvh.12917","article-title":"Shortened Therapy of Eight Weeks With Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir is Highly Effective in People With Recent HCV Genotype 1 Infection","volume":"25","author":"Martinello","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/bs.armc.2021.09.004_bb0925","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/hep4.1480","article-title":"Chronic Viral Hepatitis: Current Management and Future Directions","volume":"4","author":"Do","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb0930","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/Pibrentasvir for 8Weeks in Treatment-Na\u00efve Patients With Chronic HCV Genotypes 1-6 and Compensated Cirrhosis: The Expedition-8 Trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0935","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.28844","article-title":"Sofosbuvir and Ribavirin for 6 Weeks is Not Effective Among People With Recent hepatitis C Virus Infection: The DARE-C II Study","volume":"64","author":"Martinello","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/bs.armc.2021.09.004_bb0940","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir Plus Sofosbuvir Fixed-Dose Combination for 6 Weeks in Patients With Acute Hepatitis C Virus Genotype 1 Monoinfection (HepNet Acute HCV IV): An Open-Label, Single-Arm, Phase 2 Study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb0945","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir-Sofosbuvir for 6 Weeks to Treat Acute Hepatitis C Virus Genotype 1 or 4 Infection in Patients With HIV Coinfection: An Open-Label, Single-Arm Trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0950","article-title":"Restoration of HCV-Specific Immune Responses With Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection","volume":"8","author":"Casey","year":"2019","journal-title":"Cell"},{"key":"10.1016\/bs.armc.2021.09.004_bb0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232773","article-title":"Treatment and Re-treatment Results of HCV Patients in the DAA Era","volume":"15","author":"Piecha","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.armc.2021.09.004_bb0960","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb0965","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00535-019-01575-9","article-title":"Initial- and Re-treatment Effectiveness of Glecaprevir and Pibrentasvir for Japanese Patients With Chronic Hepatitis C Virus-Genotype 1\/2\/3 Infections","volume":"54","author":"Sezaki","year":"2019","journal-title":"J. Gastroenterol."},{"issue":"63","key":"10.1016\/bs.armc.2021.09.004_bb0970","doi-asserted-by":"crossref","first-page":"13197","DOI":"10.1021\/acs.jmedchem.0c01877","article-title":"Nobel Prize in Physiology or Medicine","volume":"2020","author":"Meanwell","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0975","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","article-title":"Hepatitis C Virus Elimination: Laying the Foundation for Achieving 2030 Targets","volume":"18","author":"Dore","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/bs.armc.2021.09.004_bb0985","doi-asserted-by":"crossref","first-page":"10563","DOI":"10.1021\/acs.jmedchem.9b01562","article-title":"Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate","volume":"62","author":"Ramdas","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.armc.2021.09.004_bb0990","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1021\/acs.jmedchem.0c00082","article-title":"Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb0995","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1021\/acs.jmedchem.9b02176","article-title":"GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage","volume":"63","author":"Kazmierski","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1000","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1021\/acs.jmedchem.0c00956","article-title":"Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)","volume":"63","author":"Randolph","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1005","doi-asserted-by":"crossref","first-page":"14740","DOI":"10.1021\/acs.jmedchem.0c01296","article-title":"Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3\/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1010","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.1c00554","article-title":"Discovery of Quinoxaline-Based P1\u2013P3 Macrocyclic NS3\/4A Protease Inhibitors With Potent Activity Against Drug-Resistant Hepatitis C Virus Variants","volume":"64","author":"Nageswara Rao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1015","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1021\/acs.jmedchem.9b00143","article-title":"Synthesis and Anti-HCV Activities of 4\u2032-Fluoro-2\u2032-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4\u2032-Fluoro-2\u2032-C-methyluridine 5\u2032-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1020","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.8b01300","article-title":"Discovery of a Series of 2'-Alpha-Fluoro,2'-Beta-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus","volume":"62","author":"Mengshetti","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1025","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1021\/acs.jmedchem.0c00935","article-title":"Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227104","article-title":"Preclinical Evaluation of AT-527, a Novel Guanosine Nucleotide Prodrug With Potent, Pan-Genotypic Activity Against Hepatitis C Virus","volume":"15","author":"Good","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.armc.2021.09.004_bb1035","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.jmedchem.8b01719","article-title":"Design of N-Benzoxaborole Benzofuran GSK8175\u2014Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor","volume":"62","author":"Chong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1040","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1021\/acs.jmedchem.0c00232","article-title":"2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action","volume":"63","author":"Jiang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1045","doi-asserted-by":"crossref","first-page":"9431","DOI":"10.1021\/acs.jmedchem.1c00696","article-title":"Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly","volume":"64","author":"Rolt","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1050","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1021\/acs.jmedchem.9b00091","article-title":"Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/01652176.2017.1343516","article-title":"Rabies\u2014Epidemiology, Pathogenesis, Public Health Concerns and Advances in Diagnosis and Control: A Comprehensive Review","volume":"37","author":"Singh","year":"2017","journal-title":"Vet. Q."},{"key":"10.1016\/bs.armc.2021.09.004_bb1065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13365-015-0351-1","article-title":"Diabolical Effects of Rabies Encephalitis","volume":"22","author":"Jackson","year":"2016","journal-title":"J. Neurovirol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-Exposure Rabies Prophylaxis: A Systematic Review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/bs.armc.2021.09.004_bb1075","doi-asserted-by":"crossref","first-page":"A107","DOI":"10.1016\/j.vaccine.2019.01.041","article-title":"Rabies Post-Exposure Prophylaxis: A Systematic Review on Abridged Vaccination Schedules and the Effect of Changing Administration Routes During a Single Course","volume":"37","author":"Kessels","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/bs.armc.2021.09.004_bb1080","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1099\/jgv.0.001269","article-title":"Trying to Treat the Untreatable: Experimental Approaches to Clear Rabies Virus Infection From the CNS","volume":"100","author":"Smith","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.12.009","article-title":"Status of Antiviral Therapeutics Against Rabies Virus and Related Emerging Lyssaviruses","volume":"35","author":"Du Pont","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2851","article-title":"Antiviral Therapy for Human Rabies","volume":"20","author":"Appolinario","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/bs.armc.2021.09.004_bb1095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.03.011","article-title":"Ribavirin-Related Compounds Exert In Vitro Inhibitory Effects Toward Rabies Virus","volume":"154","author":"Anindita","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb1100","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb1105","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1016\/j.vaccine.2017.10.109","article-title":"Re-Evaluating the Effect of Favipiravir Treatment on Rabies Virus Infection","volume":"37","author":"Banyard","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/bs.armc.2021.09.004_bb1110","doi-asserted-by":"crossref","first-page":"104641","DOI":"10.1016\/j.antiviral.2019.104641","article-title":"Reevaluation of the Efficacy of Favipiravir Against Rabies Virus Using In Vivo Imaging Analysis","volume":"172","author":"Yamada","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb1115","doi-asserted-by":"crossref","first-page":"105016","DOI":"10.1016\/j.antiviral.2021.105016","article-title":"Broad Spectrum Compounds Targeting Early Stages of Rabies Virus (RABV) Infection","volume":"188","author":"Kali","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb1120","first-page":"e00320","article-title":"Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor","volume":"94","author":"Pont","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1125","doi-asserted-by":"crossref","first-page":"30529","DOI":"10.1038\/srep30529","article-title":"Viperin Inhibits Rabies Virus Replication Via Reduced Cholesterol and Sphingomyelin and is Regulated Upstream by TLR4","volume":"6","author":"Tang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.armc.2021.09.004_bb1130","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41586-018-0238-4","article-title":"A Naturally Occurring Antiviral Ribonucleotide Encoded by the Human Genome","volume":"558","author":"Gizzi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb1135","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1021\/jacs.1c01045","article-title":"The Antiviral Enzyme, Viperin, Activates Protein Ubiquitination by the E3 Ubiquitin Ligase, TRAF6","volume":"143","author":"Patel","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/bs.armc.2021.09.004_bb1140","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S1473-3099(20)30052-9","article-title":"Measles Eradication-Retreating is Not an Option","volume":"20","author":"Durrheim","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb1145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41591-021-01237-5","article-title":"A Dangerous Measles Future Looms Beyond the COVID-19 Pandemic","volume":"27","author":"Durrheim","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb1150","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41591-021-01430-6","article-title":"Emergence of Measles During the COVID-19 Pandemic Threatens Pakistan's Children and the Wider Region","volume":"27","author":"Rana","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb1155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.pcl.2012.07.007","article-title":"Ethical Issues in Neonatal and Pediatric Clinical Trials","volume":"59","author":"Laventhal","year":"2012","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/bs.armc.2021.09.004_bb1160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/v11111017","article-title":"Measles Encephalitis: Towards New Therapeutics","volume":"11","author":"Ferren","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/bs.armc.2021.09.004_bb1165","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1128\/AAC.49.9.3755-3761.2005","article-title":"Design of a Small-Molecule Entry Inhibitor With Activity Against Primary Measles Virus Strains","volume":"49","author":"Plemper","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.armc.2021.09.004_bb1170","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1021\/jm0602559","article-title":"Nonpeptide Inhibitors of Measles Virus Entry","volume":"49","author":"Sun","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1175","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.armc.2021.09.004_bb1180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2018.03.009","article-title":"Susceptibility of Paramyxoviruses and Filoviruses to Inhibition by 2'-Monofluoro- and 2'-Difluoro-4'-Azidocytidine Analogs","volume":"153","author":"Lo","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb1185","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1021\/jm201699w","article-title":"Non-nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase: Synthesis, Structure\u2013Activity Relationships, and Pharmacokinetics","volume":"55","author":"Ndungu","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1190","doi-asserted-by":"crossref","first-page":"232ra252","DOI":"10.1126\/scitranslmed.3008517","article-title":"An Orally Available, Small-Molecule Polymerase inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model","volume":"6","author":"Krumm","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.armc.2021.09.004_bb1195","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1038\/s41467-021-25497-4","article-title":"Small-Molecule Polymerase Inhibitor Protects Non-Human Primates From Measles and Reduces Shedding","volume":"12","author":"Wittwer","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.armc.2021.09.004_bb1200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009371","article-title":"Therapeutic Targeting of Measles Virus Polymerase With ERDRP-0519 Suppresses All RNA Synthesis Activity","volume":"17","author":"Cox","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.armc.2021.09.004_bb1205","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41564-020-0752-7","article-title":"Orally Efficacious Broad-Spectrum Allosteric Inhibitor of Paramyxovirus Polymerase","volume":"5","author":"Cox","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020069","article-title":"Potent Host-Directed Small-Molecule Inhibitors of Myxovirus RNA-Dependent RNA-Polymerases","volume":"6","author":"Krumm","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.armc.2021.09.004_bb1215","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00218","article-title":"Use of Acid Ceramidase and Sphingosine Kinase Inhibitors as Antiviral Compounds Against Measles Virus Infection of Lymphocytes In Vitro","volume":"7","author":"Grafen","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1220","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"V. The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1225","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and Evolution of Pathogenic Coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1250","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftaa033","article-title":"SARS, MERS and COVID-19: Clinical Manifestations and Organ-System Complications: A Mini Review","volume":"78","author":"Gerges Harb","year":"2020","journal-title":"Pathog. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb1255","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/JVI.06540-11","volume":"86","author":"Woo","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1260","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41564-020-0771-4","article-title":"Evolutionary Origins of the SARS-CoV-2 Sarbecovirus Lineage Responsible for the COVID-19 Pandemic","volume":"5","author":"Boni","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/d41586-021-00958-4","article-title":"The Race for Antiviral Drugs to Beat COVID\u2014and the Next Pandemic","volume":"592","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.armc.2021.09.004_bb1270","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543776.2020.1772231","article-title":"SARS, MERS and SARS-CoV-2 (COVID-19) Treatment: A Patent Review","volume":"30","author":"Nascimento Junior","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/bs.armc.2021.09.004_bb1275","doi-asserted-by":"crossref","first-page":"100721","DOI":"10.1016\/j.drup.2020.100721","article-title":"Current Status of Antivirals and Druggable Targets of SARS CoV-2 and Other Human Pathogenic Coronaviruses","volume":"53","author":"Artese","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/bs.armc.2021.09.004_bb1280","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved \u03b1-Ketoamide Inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.armc.2021.09.004_bb1285","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1290","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/acsinfecdis.0c00761","article-title":"Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity Against Coronaviruses","volume":"7","author":"Hu","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb1295","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101555118","article-title":"Postinfection Treatment With a Protease Inhibitor Increases Survival of Mice With a Fatal SARS-CoV-2 Infection","volume":"118","author":"Dampalla","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.armc.2021.09.004_bb1300","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1305","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-Dependent RNA Polymerase From COVID-19 Virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.armc.2021.09.004_bb1310","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir Against COVID-19 and Other Viral Diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/bs.armc.2021.09.004_bb1315","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (Previously 2019-nCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/bs.armc.2021.09.004_bb1320","doi-asserted-by":"crossref","first-page":"127885","DOI":"10.1016\/j.bmcl.2021.127885","article-title":"Design, Synthesis and Biological Evaluation of 2-Aminoquinazolin-4(3H)-one Derivatives as Potential SARS-CoV-2 and MERS-CoV Treatments","volume":"39","author":"Lee","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.armc.2021.09.004_bb1325","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/bs.armc.2021.09.004_bb1330","article-title":"Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy","author":"Pillaiyar","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.armc.2021.09.004_bb1335","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acschembio.0c00875","article-title":"A Clinical-Stage Cysteine Protease Inhibitor Blocks SARS-CoV-2 Infection of Human and Monkey Cells","volume":"16","author":"Mellott","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/bs.armc.2021.09.004_bb1340","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1021\/acsinfecdis.0c00491","article-title":"Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry","volume":"7","author":"Firpo","year":"2021","journal-title":"ACS Infect. Dis."}],"container-title":["Annual Reports in Medicinal Chemistry","Coronaviruses and other Novel Antiviral Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065774321000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065774321000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:54:44Z","timestamp":1753880084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065774321000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323915113"],"references-count":254,"URL":"https:\/\/doi.org\/10.1016\/bs.armc.2021.09.004","relation":{},"ISSN":["0065-7743"],"issn-type":[{"value":"0065-7743","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}